Virtual Library
Start Your Search
M. Masuda
Author of
-
+
P1.05 - Early Stage NSCLC (ID 691)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.05-018 - Prognostic Impact of Tumor Shadow Disappearance Rate in Patients with Clinical IA Lung Adenocarcinoma (ID 8092)
09:30 - 09:30 | Author(s): M. Masuda
- Abstract
Background:
The aim of this study was to clarify whether tumor shadow disappearance rate (TDR) or consolidation to tumor diameter ratio (CTR) predict outcomes in patients with clinical stage IA lung adenocarcinoma.
Method:
We reviewed 250 patients with completely resected clinical stage IA lung adenocarcinoma between 2007 and 2014 and examined the prognostic impact of TDR and CTR. We classified all tumors into each two groups based on the TDR and CTR on high-resolution computed tomography: TDR >50% (Group A, n=77), TDR ≤50% (Group B, n=173), CTR <0.5 (Group C, n=33), and CTR ≥0.5 (Group D, n=217). TDR and CTR were calculated using the following formulas: TDR = 100 – (tumor size on mediastinal window/tumor size on lung window) ´ 100 and CTR = maximum diameter of consolidation/maximum tumor diameter.
Result:
The study group comprised 117 men (47%) and 133 women (53%), with a median age of 66 years (range, 36-83 years). The median follow-up was 50 months (range, 1 to 110 months). The disease-free survival rate at 5 years was 100%, 78.2%, 100%, and 82.5% in Groups A, B, C, and D, respectively. The lung cancer-specific survival rate at 5 years was 100%, 94.8%, 100%, and 95.9% in Groups A, B, C, and D, respectively. Multivariate analysis showed that the following factors were significant predictors of recurrence: lymph-node metastasis, lymphatic vessel invasion, blood vessel invasion, and TDR (TDR: hazard ratio=3.61, 95% confidence interval: 1.01-12.8, p=0.048). On the other hand, multivariate analysis revealed that lymph-node metastasis and TDR were significant predictors of lung cancer-specific mortality (TDR: hazard ratio=23.85, 95% confidence interval: 1.22-466.5, p=0.037).
Conclusion:
TDR is a significant predictor of not only recurrence but also lung cancer-specific mortality in patients with clinical stage IA lung adenocarcinoma.
-
+
P3.15 - SCLC/Neuroendocrine Tumors (ID 731)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.15-012 - Surgical Outcome in Early Stage Small Cell Lung Cancer (ID 10501)
09:30 - 09:30 | Author(s): M. Masuda
- Abstract
Background:
Chemo-radiation is considered to be the standard treatment for the management of limited disease of small cell lung cancer (SCLC). Even in this early stage, the role of surgery in SCLC is still controversial. We sought to examine the role of surgery; complete resection in terms of survival in SCLC.
Method:
A retrospective review was undertaken of patients who underwent surgery for SCLC between 2001 and 2015. Patients were staged according to the 7[th] edition of the Tumor, Node, Metastasis classification of lung cancer. Actuarial survival estimated with Kaplan Meier method and comparisons were undertaken using Cox regression hazard model. Clinicopathological factors and predictors of survival were analyzed.
Result:
We identified 49 patients who underwent complete resection. The mean follow up period was 1343 days. The mean age was 70.7 years. 40 patients were men and 9 were women. The number of patients of clinical stage was stage IA :21, IB: 15, IIA: 4, IIB: 6, IIIA:3. Operative procedure was lobectomy in 43, segmentectomy in 1, wedge resection in 5. The number of patients of pathological stage was stage IA :15, IB: 11, IIA: 14, IIB: 7, IIIA:2. Adjuvant chemotherapy was performed in 26 patients (53.1%). The 5-year overall survival (OS) rate in all patients was 58.8%. The 5-year OS was 61.3% in c-stage I, 54.5% in c-stage II, and 50% in c-stage III. The 5-year OS were 66.2% in p-stage I, 55.4% in p-stage II, and 50% in p-stage III. The 5-year OS of patients with adjuvant chemotherapy was significantly better than that of patients without adjuvant chemotherapy (77.8% vs. 39.8%, p=0.005). Multivariable Cox regression hazard model demonstrated that adjuvant chemotherapy was prognostic factor of overall survival (OS) (hazard ratio 0.255 (.095-.688), p=0.007)
Conclusion:
Surgical outcome for early stage SCLC was satisfied one. The role of surgery for this group seemed to be important. Adjuvant chemotherapy may improve prognosis and long-term survival will be expected.
